JP2018516849A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516849A5
JP2018516849A5 JP2017550514A JP2017550514A JP2018516849A5 JP 2018516849 A5 JP2018516849 A5 JP 2018516849A5 JP 2017550514 A JP2017550514 A JP 2017550514A JP 2017550514 A JP2017550514 A JP 2017550514A JP 2018516849 A5 JP2018516849 A5 JP 2018516849A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550514A
Other languages
English (en)
Japanese (ja)
Other versions
JP7327897B2 (ja
JP2018516849A (ja
Filing date
Publication date
Priority claimed from GBGB1505239.2A external-priority patent/GB201505239D0/en
Application filed filed Critical
Publication of JP2018516849A publication Critical patent/JP2018516849A/ja
Publication of JP2018516849A5 publication Critical patent/JP2018516849A5/ja
Application granted granted Critical
Publication of JP7327897B2 publication Critical patent/JP7327897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017550514A 2015-03-27 2016-03-23 Acheのt14ペプチドを認識する抗体 Active JP7327897B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1505239.2A GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody
GB1505239.2 2015-03-27
GB1600871.6 2016-01-18
GB1600871.6A GB2541477A (en) 2015-03-27 2016-01-18 Antibody
PCT/GB2016/050804 WO2016156803A1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache

Publications (3)

Publication Number Publication Date
JP2018516849A JP2018516849A (ja) 2018-06-28
JP2018516849A5 true JP2018516849A5 (https=) 2019-04-25
JP7327897B2 JP7327897B2 (ja) 2023-08-16

Family

ID=53178191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550514A Active JP7327897B2 (ja) 2015-03-27 2016-03-23 Acheのt14ペプチドを認識する抗体

Country Status (13)

Country Link
US (1) US10954306B2 (https=)
EP (1) EP3274371B1 (https=)
JP (1) JP7327897B2 (https=)
KR (1) KR102626626B1 (https=)
CN (1) CN107531796A (https=)
AU (1) AU2016240020B2 (https=)
BR (1) BR112017020769A2 (https=)
CA (1) CA2979972A1 (https=)
ES (1) ES2952723T3 (https=)
GB (2) GB201505239D0 (https=)
MX (1) MX392158B (https=)
RU (1) RU2729491C2 (https=)
WO (1) WO2016156803A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
GB2546773B (en) * 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer
GB201705044D0 (en) * 2017-03-29 2017-05-10 Neuro-Bio Ltd Biomarker
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
GB202112831D0 (en) * 2021-09-09 2021-10-27 Neuro Bio Ltd Biomarker
GB202113941D0 (en) 2021-09-29 2021-11-10 Neuro Bio Ltd Skin biomarker
CN120187864A (zh) 2022-09-08 2025-06-20 神经生物有限公司 使用t14肽诊断阿尔茨海默症的侧向流装置
GB202308779D0 (en) * 2023-06-13 2023-07-26 Neuro Bio Ltd Aptamer
GB202308799D0 (en) 2023-06-13 2023-07-26 Neuro Bio Ltd Neurodegenerative disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) * 1996-03-22 1996-05-22 Isis Innovation Active peptide
EP1269201A1 (en) 2000-03-29 2003-01-02 Synaptica Limited Alpha 7 nicotinic receptor screening assays
GB0028578D0 (en) * 2000-11-23 2001-01-10 Synaptica Ltd Screening assays
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
JP5186372B2 (ja) * 2005-08-16 2013-04-17 ジェネンテック, インコーポレイテッド 細胞/組織においてgalnac−t14発現を試験することによるapo2l/trailに対するアポトーシス感受性
GB0708646D0 (en) * 2007-05-04 2007-06-13 Enkephala Ltd Biologically active C-terminal fragment of acetylcholinesterase
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
CN101530162B (zh) * 2008-03-10 2011-11-23 北京大北农科技集团股份有限公司 一种新型蛋白饲料添加剂的制备方法

Similar Documents

Publication Publication Date Title
JP2018516849A5 (https=)
US11022618B2 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
Wang-Dietrich et al. The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease
Davies et al. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies
Collins et al. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
US6680173B2 (en) Diagnosis of tauopathies
RU2017133649A (ru) Антитело, которое распознает пептид т14 асне
Rosen et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease
Satoh et al. TMEM106B expression is reduced in Alzheimer’s disease brains
TWI569014B (zh) 神經退化性疾病個體之抗體可辨識之小分子之鑑定
Wittenberg et al. Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases
US20140024053A1 (en) Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
US20230220401A1 (en) Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
JP7645514B2 (ja) 神経系細胞に由来する細胞外小胞の回収方法
JP5934183B2 (ja) ミオパチーを特性化するための組成物及び方法
EP2769220B1 (en) Biomarker for autoimmune disease
Wang et al. Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease
JP2025533674A (ja) 神経変性疾患の診断におけるディスコイジンドメイン受容体2の使用及び関連するコンピュータ読取可能な媒体
US20220260593A1 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
US20230190967A1 (en) Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent
DK2646462T3 (en) METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY
CN120187864A (zh) 使用t14肽诊断阿尔茨海默症的侧向流装置
CN105556306B (zh) 用于监测多发性硬化(ms)的方法和预后试剂盒
Choi TDP-43 as a Fluid Biomarker in Amyotrophic Lateral Sclerosis
Schmidt Identification of vascular endothelial growth factor receptor 3 (VEGFR3) as an in vitro and in vivo substrate of the Alzheimer's Disease linked protease BACE2